We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Sankyo and Metabasis Therapeutics jointly announced that Sankyo plans to resume
full development of CS-917, including a Phase IIb clinical trial expected to
begin in the fourth quarter.
Vertex Pharmaceuticals announced that its collaborator, GlaxoSmithKline, has
received fast-track designation for the HIV protease inhibitor (PI) 640385 (VX-385)
from the FDA.
OncoGenex Technologies announced the initiation of a Phase II clinical trial
of OGX-011 in newly diagnosed, previously untreated patients with clinically
localized, high-risk prostate carcinoma.
Genentech has announced positive results from the Phase III MARINA study of
the investigational anti-VEGF drug Lucentis in patients with wet age-related
macular degeneration (AMD).
Alkermes and Eli Lilly announced the initiation of a Phase III trial required
for registration for their inhaled insulin system, which is being investigated
as an innovative treatment option for diabetes.
Encysive Pharmaceuticals announced that the FDA's Cardio-Renal Division stated that it anticipates filing Encysive's New Drug Application (NDA) for Thelin (sitaxsentan) on July 23, 2005, under a standard review classification.
XOMA has terminated its exclusive worldwide license agreement with Zephyr Sciences for the research, development and commercialization of products related to bactericidal/permeability-increasing protein (BPI), including its Neuprex product.